SG Americas Securities LLC Sells 27,833 Shares of Tarsus Pharmaceuticals, Inc. $TARS

SG Americas Securities LLC lessened its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 81.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,179 shares of the company’s stock after selling 27,833 shares during the period. SG Americas Securities LLC’s holdings in Tarsus Pharmaceuticals were worth $367,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Capricorn Fund Managers Ltd bought a new position in shares of Tarsus Pharmaceuticals in the third quarter valued at approximately $14,264,000. TFG Asset Management GP Ltd increased its holdings in Tarsus Pharmaceuticals by 40.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 250,000 shares of the company’s stock valued at $10,128,000 after purchasing an additional 71,530 shares in the last quarter. Allianz Asset Management GmbH bought a new position in Tarsus Pharmaceuticals in the 2nd quarter valued at $227,000. Jump Financial LLC raised its position in Tarsus Pharmaceuticals by 385.9% in the 2nd quarter. Jump Financial LLC now owns 237,117 shares of the company’s stock valued at $9,606,000 after purchasing an additional 188,317 shares during the last quarter. Finally, Norges Bank acquired a new position in Tarsus Pharmaceuticals in the second quarter worth $19,095,000. Institutional investors own 90.01% of the company’s stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 7,397 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the completion of the sale, the insider directly owned 38,958 shares of the company’s stock, valued at $3,120,535.80. The trade was a 15.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the transaction, the chief executive officer directly owned 857,991 shares in the company, valued at $70,792,837.41. The trade was a 0.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 8.97% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TARS. Barclays initiated coverage on Tarsus Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $100.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $51.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 6th. Guggenheim increased their price target on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, HC Wainwright raised their price target on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $79.86.

Tarsus Pharmaceuticals Trading Down 3.8%

TARS opened at $68.36 on Monday. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. The company has a market cap of $2.90 billion, a price-to-earnings ratio of -33.84, a price-to-earnings-growth ratio of 0.99 and a beta of 0.59. The firm has a 50 day simple moving average of $78.62 and a 200 day simple moving average of $64.71. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $38.51 and a fifty-two week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. The firm had revenue of $118.70 million for the quarter, compared to analysts’ expectations of $114.22 million. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. On average, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.